Loading
A phase 3 trial of Equecabtagene autoleucel, Daratumumab, Pomalidomide in multiple myeloma, run by Nanjing IASO Biotechnology Co., Ltd., now recruiting.
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) is a phase 3 interventional study registered as NCT06464991 by Nanjing IASO Biotechnology Co., Ltd., with 240 participants planned, started 2024-03-27 and due to reach its primary completion in 2027-08. Interventions recorded: Equecabtagene Autoleucel Injection, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Hospital-made CAR-T under one shared regulatory master file, Hospital-based CAR-T manufacturing at cost through a public network, Pomalidomide, Bortezomib.
Shares Pomalidomide, Daratumumab, Bortezomib, Dexamethasone.
Shares Hospital-made CAR-T under one shared regulatory master file, Hospital-based CAR-T manufacturing at cost through a public network, Relapsed or refractory multiple myeloma, CAR-T cell therapy.
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
Shares Pomalidomide, Daratumumab, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Daratumumab, Bortezomib, Dexamethasone.
Shares Pomalidomide, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.